| P/E (FY) | — | Sales (TTM) | $236,561 |
| Earnings (TTM) | -$715,690 | ROE | — |
| Net Margin | −538.76% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 23.52% |
| Market Cap | $51,196 | Trading Days | 2508 |
| 52W High | 0.09 |
| 52W Low | 0.00 |
| % Off High | −99.89% |
| YTD | −98.65% | 1Y | −99.88% |
| 3Y | −99.99% | 5Y | −100.00% |
| 10Y | −100.00% | Since incept. (ann.) | −73.50% |
| Ann. Volatility (1Y) | 397.84% | Ann. Volatility (3Y) | 328.90% |
| Sharpe (1Y) | 0.05 | Sharpe (3Y) | 0.53 |
| Max Drawdown (1Y) | −99.88% | Max Drawdown (3Y) | −99.99% |
| Beta (3Y, vs SPY) | −1.05 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LIPO | LIPELLA PHARMACEUTICALS INC. | $151,101 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $685,993 | — |
| ZVSA | ZyVersa Therapeutics, Inc. | $939,127 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $988,490 | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $1.3M | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $1.9M | — |
| BPTH | BIO-PATH HOLDINGS, INC. | $2.0M | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $2.1M | — |
| AZTR | Azitra, Inc. | $2.1M | — |
| DCOY | Decoy Therapeutics Inc. | $2.1M | — |
| NXTS | Nexentis Technologies Inc. |
| $2.2M |
| — |
| VCNX | VACCINEX, INC. | $2.2M | — |
